Cinclus Pharma Q2 Report 2024

Webcast August 29, 2024, 13:00

Presenters:

Christer Ahlberg, CEO
Maria Engström, CFO

Disclaimer

IMPORTANT: You must read the following before continuing. The following applies to this document, the oral presentation of the information in this document by Cinclus Pharma Holding AB (publ), Reg. No. 559136-8765 (the "**Company**" and together with its subsidiaries, the "**Group**") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "**Information**"). In accessing the Information, you agree to be bound by the following terms and conditions.

The Information is not intended for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Australia, Canada, the Hong Kong Special Administrative Region of the People's Republic of China, Japan and South Africa or any other jurisdiction where such distribution would be unlawful. This presentation is not a prospectus or similar document, and it has not been approved, registered or reviewed by the Swedish Financial Supervisory Authority nor any governmental authority or stock exchange in any jurisdiction.

The Information has been prepared by the Company and is intended to present background information on the Company, its business and the industry in which it operates. The Information contains summary information only and does not purport to be comprehensive and is not intended to be (and should not be used as) the sole basis of any analysis or other evaluation. The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained therein shall form the basis of or be relied on in connection with any investment activity. The Company shall not have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of the Information or otherwise arising in connection with this presentation.

By accessing this Information, you represent that such access does not violate any registration requirements or other legal restrictions in the jurisdiction in which you reside or conduct business. It is especially noted that the Information may not be accessed by persons within the United States or "U.S. Persons" (as defined in Regulation S under the Securities Act of 1933, as amended (the "**Securities Act**") unless they are qualified institutional buyers "QIBs" as defined in Rule 144A under the Securities Act. By accessing the Information, you represent that you are (i): a non-U.S. person that is outside the United States or (ii) a QIB. Further, the Information may not be accessed by persons within the United Kingdom unless they are persons with professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the "**Order**"), a "qualified investors" falling within Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 ("**EUWA**"), or high net worth entities falling within Article 49(2)(a) to (d) of the Order (each a "**Relevant Person**"). By accessing the Information, you represent that you are: (i) outside the United Kingdom or (ii) a Relevant Person.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. As a result, you are cautioned not to place undue reliance on such forward-looking statements.

No representation, warranty or undertaking, express or implied, is made by or on behalf of the Company as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained therein. The Information has not been independently verified and will not be updated. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results. The Company expressly disclaim any obligation or undertaking to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result from any change in the Company's expectations, any change in events, conditions or circumstances on which these forward-looking statements are based, or other events or circumstances arising after the date of this document. Market data used in the Information not attributed to a specific source are estimates of the Company and have not been independently verified.

Focus on the unmet medical need, where 24 hr acid control is most important

Linaprazan glurate

Potential to become **best in class** and the **first innovative MoA** [1] in gastric acid related disorders in over 25 years

Focus on Healing of Severe Patients, *the* Unmet Medical Need in eGERD

Enables Specialty Commercial Focus

Greatest differentiation from PPIs[2] and 1st generation PCABs[3] → strong competitive position

Strong Phase II data point the way for phase III

Phase III studies to start in 2025, successful end of phase II meeting in the end of 2023

A scientifically de-risked development program

Strong Investor Base

Backed by **life science focused institutional investors** Trill Impact Ventures, AP4, Linc and Eir Ventures

Note: 1) MoA: Mechanism of Action. 2) PPI: Proton Pump Inhibitor. 3) PCAB = Potassium-Competitive Acid Blocker.

Blockbuster market potential in severe eGERD in USA & EU



Assuming Gross Price per tablet: USA $21,7 EU €3 - Healing b.i.d2) - Maintenance q.d.3)
Cost of healing of eGERD patients c. USD 1,215 per healing cycle – c. 1-2 cycles per year

Note: Data projected with respect to year 2025. 1) People above 18 years of age. 2) b.i.d.: twice daily, 3) q.d.: once daily. Source: Apex/IQVIA Market Reports 2022-2023. US Census Bureau International Database.

Linaprazan glurate: Potential to be best in class 2nd generation PCAB

Cinclus Pharma

	PHARMACOLOGICAL (PRODRUG) ADVANTAGES PROVIDES...				... CLINICAL ADVANTAGES AND SUPERIORITY PROFILE				
	DOSING INDEPENDENT OF MEAL	TIME TO PH>4 After 1st dose	TIME TO FULL EFFECT PH>4 24hrs/day	24 HOURS ACID CONTROL	HEALING EFFECT DIFFERENCE VS. PPIs (Lansoprazole)	TIIME TO HEALING Weeks	SUPERIORITY IN HEALING PHASE vs. PPIs	SUPERIOR DAY-TIME SYMPTOM RELIEF vs. PPI	SUPERIOR NIGHT-TIME SYMPTOM RELIEF vs. PPI
PPIs (e.g., Lansoprazole FDA label)	✗	+4 hrs	3-5 DAYS[1]	~40–70%[2]	✗	8	✗	✗	✗
Vonoprazan (FDA label) (1st generation PCAB)	✓	2-4 hrs	up to 7 days	~63-85%[3]	18-20%p in 2 & 8 weeks	8	✗	✗	✗
Linaprazan glurate (Expected FDA label) (2nd generation PCAB)[4]	✓	1-2 hrs *Fastest symptom relief*	1-2 hrs *Fastest healing*	92-96%	52%p in 4 weeks	4 *Healing in half the time*	✓	✓	✓

Linaprazan glurate is, unlike 1st generation PCABs, developed for healing of patients with severe eGERD - aiming to become superior compared to existing medication

Source: 1) Scarpignato C and Hunt R, Current Opinion in Pharmacology (2008). 2) Miner P, et al, Am J Gastro (2003). 3) Phathom Pharmaceuticals, Voquezna (Vonoprazan) FDA label 2023. 4) Cinclus Pharma phase I data on file (formulation B).

Specialist GI targeted commercialization approach maximizes Cinclus Pharma optionality post-data

Cinclus Pharma

Specialist GI approach

Effective market entry

Accessible with a highly focused sales & marketing team

Non-targeted approach

Requiring Big Pharma reach

Requires significant sales & marketing resources; large primary care sales force, DTC campaigns, etc.



Effective go-to-market approach

- Specialist GI approach…

The concentrated Specialist GI prescribers' community can be targeted with a lower number of sales reps - a specialty pharma approach targeting science driven specialist

- …enabling faster market penetration…

Patients are already identified and treated by specialist GI prescribers, enabling faster market penetration post approval

- …with high post-data optionality

All the commercial rights are still in the company, creating high go-to-market and business development optionality post first data in 2026

Initial Indication aspiration

Treatment of erosive Gastro- esophageal reflux disease (eGERD) all grades A-D

With focus on healing of severe eGERD and …

… Accomplished 24hr pH control in clinical studies

…Aiming to show superior Healing in severe eGERD (C&D)

… Aiming to show superior symptom control with focus on night time symptoms

…Healing in half the time (4 vs 8 weeks) vs PPIs and other PCABs

Dual Treatment of Helicobacter pylori
(Linaprazan glurate plus amoxicillin)

With focus to become …

..the new first line treatment

Due to as good as or better HP eradication with less risk of antibiotic resistance vs current standard of care

Strategic roadmap with dense upcoming news flow



Note: Illustrative guidance on timing, not exact dates. The information on this slide contains forward-looking statements based on estimates and assumptions and is subject to change. Timing of the second eGERD Phase III study as well as the *H. pylori* studies may be adjusted based on financing.

Summary of key events Q2, 2024

- Successful investor roadshows and completion of IPO
  - SEK 715m before cost raised on Nasdaq Stockholm, midcap
  - Market cap approx. SEK 1.5bn, end Aug 2024
- Two of the company's Phase I studies (BA and PK/PD) were completed during the period.
- The PK/PD study have been submitted for a presentation at UEGW, a scientific congress within the gastroenterology area, later this year.
- Two of the company's pre-clinical studies (photo- and co-toxicological studies) were also completed during the quarter with good results.
- During the period, the company received further national approvals for the formulation patent in Hong Kong and Mexico.

Post period highlights

- The Swiss company PSI CRO will serve as the clinical research organization (CRO) for the Phase III program for the treatment of eGERD.

- Study medications for phase 3 with the new further developed and better formulation under production.

Co-workers

26
Co-workers

12
employees

14
in-house consultants

Financial overview, Income statement Jan-Jun 2024

SEKm	Apr-Jun-24	Apr-Jun-23	Dev Q2	Jan-Jun-24	Jan-Jun-23	Dev H1	Jan-Dec-23	Jan-Mar-24
Net sales	0,0	3,0	-3,0	0,0	6,0	-6,0	6,0	0,0
G&A	-16,7	-12,4	-4,3	-22,3	-24,8	3	-40	-5,6
R&D	-20,8	-39,3	18,5	-51,3	-79,0	28	-167	-30,5
Other op exp/income	0,2	-1,4	1,5	0,0	-1,3	1	-1	-0,2
EBIT	**-37,3**	**-50,1**	**12,7**	**-73,6**	**-99,2**	**25,5**	**-201,0**	**-36,3**
Financial net	-2,8	-9,9	7	-3,2	-9,8	7	-13,6	-0,4
Tax	-0,2	0,1	0	-0,5	0,0	0	-0,5	-0,2
Net profit	**-40,3**	**-59,8**	**19,5**	**-77,2**	**-109,0**	**31,8**	**-215,1**	**-36,9**

- **Net sales** were zero compared with last year's SEK 6 m constituting royalties on milestone payments from Sinorda Biomedicine's commercial partner in China.
- The **operating expenses** were lower than last year:
  - The G&A expenses included one-time expenses for IPO preparations of SEK 6,9 m in H1 2024 and SEK 9,3 m in H1 2023.
  - The R&D expenses were lower mainly due to no clinical studies running in 2024. In 2023, expenses for the phase II clinical study were accounted for.
- **EBIT** increased with SEK 25,5m H1.
- **Financial net** mainly concerned the interest expenses from share-holder loan but were offset by positive unrealized currency effects.
- **Tax** concerned corporate and cantonal tax for our Swiss affiliate.
- **Net profit** increased with SEK 31,8 m

Financial overview, Financial position and Cash flow Jan-Jun 2024

SEKm	Jun 30, -24	Jun 30, -23	Dev	Dec 31, -23
Fixed assets	0,9	0,3	0,6	0,3
Other Current assets	5,2	15,4	-0,9	6,1
Cash	684,7	108,6	596,7	88,0
Total assets	**690,8**	**124,4**	**596,4**	**94,4**
Equity	637,8	29,3	714,6	-76,8
Non-current liabilities	6,8	13,7	0,0	6,8
Current liabilities	46,2	81,4	-118,2	164
Total liabilities	**690,8**	**124,4**	**596,4**	**94,4**

SEKm	Jan-Jun-24	Jan-Jun-23	Dev	Jan-Dec-23
Cash flow from operating activities	-57,4	-100,0	42,6	-209,2
Cash flow from financing activities	653,9	33,8	620,1	122,9
Total cash flow	**596,5**	**-66,3**	**662,8**	**-86,3**
Cash at the end of the period	684,7	108,6	596,7	88,0

- **Cash flow** Jan-Jun 2024 was net SEK 596,5m as a result from the new share issue in June.
- **Cash position** 30th of June was SEK 684,7m. The new share issue brought in gross SEK 715m and SEK 655m net.
- **Equity** increased with SEK 715m compared with Dec 2023 due to the new share issue and the offset issue of the share holder loan in June 2024.

Largest shareholders end of June 2024

	Number of shares	Share (%)
Trill Impact Ventures	3 721 221	8,0%
Fjärde AP-fonden	3 522 368	7,6%
Linc AB	2 114 322	4,5%
Peter Unge via company	2 050 015	4,4%
Kjell Andersson via company	1 908 000	4,1%
Mikael Dahlström estate	1 881 520	4,0%
Futur Pension	1 803 476	3,9%
Movestic Livförsäkring AB	1 725 824	3,7%
Nylof Holding AB	1 164 575	2,5%
Lennart Hansson via company	1 084 771	2,3%
Irrus Investments	982 941	2,1%
Nordnet Pension fund	902 231	1,9%
Eir Ventures I AB	898 750	1,9%
Postamentet Holding AB	688 409	1,5%
MWP Management Consulting AB	680 000	1,5%
Fifteen largest shareholders	***25 128 423***	***54,0%***
Others	21 409 366	*46,0%*
Total	**46 537 789**	**100,0%**

IPO Cornerstone investors:

- Trill Impact Ventures
- 4th AP fund
- Linc AB
- Irrus Investments
- Eir Ventures
- Regulus Pharma

Founders:

- Peter Unge
- Kjell Andersson
- Mikael Dahlström estate
- Nylof Holding AB
- Lennart Hansson
- MWP Management Consulting AB

Linaprazan Glurate: the next gold-standard in healing erosive GERD

1. Next generation PCAB targeting healing, *the* area of high unmet medical need in severe eGERD
2. Phase III ready, clear FDA regulatory pathway, first phase III readout in 2026
3. Superior acid control profile delivering fastest onset of action & time to steady state(1), crucial for healing of severe eGERD
4. In clinical trials, delivering 2x the healing effect difference vs active comparator (PPI) as compared to 1st generation PCAB
5. Blockbuster market potential in healing of severe eGERD (LA grade C/D) patients
6. Strong IP protection & 10 years data exclusivity upon market approval in EU and US

Note: 1) vs. vonoprazan

QA

Calendar

Q3 Report 2024, 14th November 2024
Year-End Report 2024, 20th February 2025

IR contact

ir@cinclupharma.com